PCSA | tickerfilter.com

Fundamental analysis

41%

Profitability 35%

Dept financing 23%

Liquidity 50%

Performance 50%

Company vs Stock growth

+ Add row to compare

Performance

5 Days

-14.78%

1 Month

15.32%

3 Months

-13.42%

6 Months

803.63%

1 Year

1,131.82%

2 Year

77.12%

Key data

Stock price

$2.71

P/E Ratio

N/A

DAY RANGE

$2.71 - $3.45

EPS

-$3.19

52 WEEK RANGE

$0.11 - $8.88

52 WEEK CHANGE

$1,128.47

MARKET CAP

0.000

YIELD

N/A

SHARES OUTSTANDING

2.660 M

DIVIDEND

N/A

EX-DIVIDEND DATE

N/A

NEXT EARNINGS DATE

05-09-2025

BETA

2.05

PUBLIC FLOAT

AVERAGE 10 VOLUME

$84,281

AVERAGE 30 VOLUME

$71,234

Company detail

CEO: David Young
Region: US
Website: processapharmaceuticals.com
Employees: 20
IPO year: 2018

Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

Processa Pharmaceuticals, Inc. focuses on the development of drug products for the treatment of patients with unmet medical needs in the United States. Its lead product candidate is PCS499, an oral tablet that is in Phase 2B clinical trials for the. treatment of ulcerative and non-ulcerative necrobiosis lipoidica, a chronic disfiguring condition. The company was incorporated in 2011 and is based in Hanover, Maryland.

PCSA - Processa Pharmaceuticals, Inc.